Skip to main content
OpenTrials
Completed

NCT Number: NCT05251363

BIOTRONIK Conduction System Pacing With the Solia Lead

The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area. Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bradycardia Arrhythmias, Cardiac Atrioventricular Block Bundle-Branch Block Cardiac Conduction System Disease Cardiomyopathies Cardiovascular Diseases Heart Block Heart Diseases Left Bundle-Branch Block Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Banner - University Medical Center Phoenix, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is a candidate for implantation of a BIOTRONIK pacemaker system, per standard guidelines. Single chamber, dual chamber, and Cardiac Resynchronization Therapy with a Pacemaker (CRT-P) systems are allowed.
  • Patient has an implant planned to utilize left bundle branch area pacing within 30 days of consent
  • Patient is able to understand the nature of the study and provide written informed consent
  • Patient is available for follow-up visits on a regular basis for the expected duration of follow-up
  • Patient accepts Home Monitoring® concept
  • Patient age is greater than or equal to 18 years at time of consent

Exclusion criteria

  • Patient meets a standard contraindication for pacemaker system implant
  • Patient is currently implanted with a pacemaker or Implantable Cardioverter-Defibrillator (ICD) device
  • Patient has had a previous unsuccessful attempt to place a lead in the LBB area
  • Patient has planned cardiac surgical procedures or interventional measures within 3 months after implant
  • Patient is expected to receive a heart transplant within 12 months
  • Patient life expectancy less than 12 months
  • Patient has the presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Patient reports pregnancy at the time of enrollment
  • Patient is enrolled in any other investigational cardiac clinical study during the course of the study

Treatment and study plan

Solia S lead

Device

The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.

Primary outcomes

  1. Serious Adverse Device Effect (SADE)-Free Rate at 3 Months

    Time frame: 3 months post implant

    The overall rate of serious Solia S Left Bundle Branch (LBB) lead related adverse device effects and serious implant procedure events related to the Solia S LBB lead that occur through 3 months post-implant. The definition of adverse device effect is an untoward medical occurrence (e.g. disease, injury) related to the use of a study device. Pacemaker lead-related examples include events such as lead dislodgements or lead malfunction. The Solia S LBB lead complication-free rate is calculated as the number of subjects without one or more adverse device effect complications divided by the total number of study subjects successfully enrolled and subjects undergoing an unsuccessful implant attempt who have a qualifying primary safety endpoint event. Classification of adverse device related events from the pool of potential events is determined by a clinical events committee (CEC). The complication-free rate is expressed in percent.

  2. Implant Success Rate of the Solia S Lead in LBB Area

    Time frame: at implant procedure

    The percentage of subjects with Solia S placed successfully in the LBBA divided by the total number of consented study subjects in whom an implant of Solia S in the LBBA was attempted.

Secondary outcomes

  1. Quality of Life (QOL) From Baseline Through 12 Months Post-Implant

    Time frame: 12 months post implant

    The change in the physical function Short Form-36 (SF-36, 36-Item Short Form Health Survey) QOL subscale was calculated as the mean change from baseline to 12-month follow-up for all subjects that completed both the baseline QOL and 12-month QOL questionnaire. The physical function subscale of Short Form-36 is comprised of ten questions out of the total of 36 questions. The responses to the ten questions relating to physical function were averaged at baseline and at 12 months. The difference in the averages (12 months minus baseline) is reported as the outcome for secondary endpoint 1. Note that each question and each component is scored such that a higher score defines a more favorable health state. Each is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.

  2. Serious Adverse Device Effect (SADE)-Free Rate at 6 Months

    Time frame: 6 months post implant

    The overall rate of serious Solia S LBBA lead related adverse device effects and serious implant procedure events related to the Solia S LBBA lead that occur through 6 months post-implant. The Solia S LBBA lead complication-free rate per subject, which was calculated as the number of subjects without one or more complications divided by the total number of study subjects successfully enrolled and subjects undergoing an unsuccessful implant attempt who have a qualifying safety endpoint event. The complication-free rate is expressed in percentage of participants without SADE.

  3. Serious Adverse Device Effect (SADE)-Free Rate at 12 Months

    Time frame: 12 months post implant

    The overall rate of serious Solia S LBBA lead related adverse device effects and serious implant procedure events related to the Solia S LBBA lead that occur through 12 months post-implant. The Solia S LBBA lead complication-free rate per subject, which was calculated as the number of subjects without one or more complications divided by the total number of study subjects successfully enrolled and subjects undergoing an unsuccessful implant attempt who have a qualifying safety endpoint event. The complication-free rate is expressed in percent.

  4. Pacing Threshold Measurements for Solia S Lead at 3 Months

    Time frame: 3 months post implant

    Pacing threshold measurements for Solia S leads implanted in the LBBA at the 3 month follow-up visit.

  5. Sensing Measurements for Solia S Lead at 3 Months

    Time frame: 3 months post implant

    R-wave sensing amplitude measurements for Solia S leads implanted in the LBBA at the 3 month follow-up visit.

  6. Pacing Impedance for Solia S Lead at 3 Months

    Time frame: 3 months post implant

    Pacing impedance measurements for Solia S leads implanted in the LBBA at the 3 month follow-up visit.

  7. Pacing Threshold Measurements for Solia S Lead at 6 Months

    Time frame: 6 months post implant

    Pacing threshold measurements for Solia S leads implanted in the LBBA at the 6 month follow-up visit.

  8. Sensing Measurements for Solia S Lead at 6 Months

    Time frame: 6 months post implant

    R-wave sensing amplitude measurements for Solia S leads implanted in the LBBA at the 6 month follow-up visit.

  9. Pacing Impedance for Solia S Lead at 6 Months

    Time frame: 6 months post implant

    Pacing impedance measurements for Solia S leads implanted in the LBBA at the 6 month follow-up visit.

  10. Pacing Threshold Measurements for Solia S Lead at 12 Months

    Time frame: 12 months post implant

    Pacing threshold measurements for Solia S leads implanted in the LBBA at the 12 month follow-up visit.

  11. Sensing Measurements for Solia S Lead at 12 Months

    Time frame: 12 months post implant

    R-wave sensing amplitude measurements for Solia S leads implanted in the LBBA at the 12 month follow-up visit.

  12. Pacing Impedance for Solia S Lead at 12 Months

    Time frame: 12 months post implant

    Pacing impedance measurements for Solia S leads implanted in the LBBA at the 12 month follow-up visit.

Sponsors and collaborators

Lead sponsor

Biotronik, Inc.

Industry

Registry information

Acronym: BIO-CONDUCT

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Feb 22, 2022
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.